Nasdaq -- ORLANDO, Fla. -(Dow Jones)- An experimental cancer drug being developed by Roche Holding AG (ROG.VX, RHHBY) and Curis Inc.(CRIS) was shown to prevent and shrink basal cell skin tumors in patients with basal cell nevus syndrome, a rare disease that significantly increases the risk of developing basel cell cancer.
